|
POU5F1P3
|
0.100 |
Biomarker
|
disease |
BEFREE |
The expression of the embryonic gene Cripto-1 is regulated by OCT4 in human embryonal carcinoma NCCIT cells.
|
29223130 |
2018 |
|
POU5F1P3
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Therefore, we examined whether allelic pairing of Oct4 loci also occurs during differentiation of F9 and P19 ECCs.
|
28967672 |
2017 |
|
POU5F1P3
|
0.100 |
Biomarker
|
disease |
BEFREE |
In fact, OCT3/4 together with SOX2 is an informative diagnostic tool for EC in a clinical setting.
|
24404135 |
2014 |
|
POU5F1P3
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Oct4 is a POU domain homeobox gene, expressed in undifferentiated embryonal carcinoma and embryonic stem cells and is quickly down-regulated upon induction of differentiation.
|
22160855 |
2012 |
|
POU5F1P3
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Taken together, our results showed that hypoxia reduces OCT4 expression levels in ECs to increase drug resistance and that these effects could be countered to ablate the suppressive effects of hypoxia on chemosensitivity.
|
23002208 |
2012 |
|
POU5F1P3
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Therefore, a site-specific, posttranslational modification of the Oct4 protein orchestrates the regulation of its stability, subcellular localization, and transcriptional activities, which collectively promotes the survival and tumorigenicity of ECCs.
|
23041284 |
2012 |
|
POU5F1P3
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
CIS, seminoma, and the undifferentiated embryonal carcinoma (EC) retain an embryonic phenotype and express pluripotency factors (NANOG/OCT4).
|
23097629 |
2012 |
|
POU5F1P3
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
OCT3/4 (POU5F1) is an established diagnostic immunohistochemical marker for specific histological variants of human malignant germ cell tumours (GCTs), including the seminomatous types and the stem cell component of non-seminomas, known as embryonal carcinoma.
|
21847120 |
2011 |
|
POU5F1P3
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The results indicate that TCF3 is an inhibitor of the malignant phenotypes of embryonal carcinoma through the regulation of Oct4 expression.
|
21725619 |
2011 |
|
POU5F1P3
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The transcriptional regulators of pluripotency, POU5F1 (OCT4), NANOG and SOX2, are highly expressed in embryonal carcinoma (EC).
|
19876845 |
2010 |
|
POU5F1P3
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
However, protein expression of OCT3/4 and AP2y was weak and these JKT-1 cells expressed SOX2, a marker of embryonal carcinoma and did not express c-KIT usually expressed in most seminoma.
|
19226408 |
2010 |
|
POU5F1P3
|
0.100 |
Biomarker
|
disease |
BEFREE |
A total of 34/43 (79%) of difficult-to-classify areas stained 3+ for OCT3/4, CD30, and SOX2, similar to embryonal carcinoma.
|
19396148 |
2009 |
|
POU5F1P3
|
0.100 |
Biomarker
|
disease |
BEFREE |
We now demonstrate reprogramming of DNA methylation and histone modifications on regulatory regions of the developmentally regulated OCT4 and NANOG genes by exposure of 293T cells to EC cell extract.
|
17314394 |
2007 |
|
POU5F1P3
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
We hypothesize that in refractory TGCTs the original tumor stem cell population of Oct-3/4-positive, cisplatin-sensitive EC cells could be replaced by an Oct-3/4-negative, resistant population in a selection process.
|
16557044 |
2006 |
|
POU5F1P3
|
0.100 |
Biomarker
|
disease |
BEFREE |
Nineteen (76%) of 25 cases revealed diffuse, moderate to strong nuclear OCT4 staining in postchemotherapy embryonal carcinomas.
|
16733205 |
2006 |
|
POU5F1P3
|
0.100 |
Biomarker
|
disease |
BEFREE |
We were able to induce loss of Oct-3/4 in a cisplatin-sensitive EC cell line resulting in a secondary cisplatin-resistant cell type with retained EC cell characteristics and changes in apoptotic signaling identical to those in primary resistant cells.
|
16557044 |
2006 |